Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer

Anti-Cancer Drugs

Volumn 16, Issue 6, 2005, Pages 609-615

  Villman, Kenneth ^a   Blomqvist, Carl ^b   Larsson, Rolf ^b   Nygren, Peter ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Cytotoxic drug; In vitro

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUORESCEIN; FLUORESCEIN DIACETATE; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE; FLUOROMETRIC MICROCULTURE CYTOTOXICITY ASSAY; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; FEMALE; FLUOROMETRY; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY CONTROL; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 20844443105     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200507000-00003     Document Type: Article

References (36)

1. National Board of Health and Welfare. The Cancer Registry. Cancer Incidence in Sweden 2001. Stockholm: National Board of Health and Welfare; 2003.
2. National Board of Health and Welfare. Causes of Death 2001. Stockholm: National Board of Health and Welfare; 2003.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 199; 47:68]. CA Cancer J Clin 1997; 47:5-27.
4. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439-3460.
5. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35:1194-11201.
6. Black MM, Speer FD. Effects of cancer chemotherapeutic agents on dehydrogenase activity of human cancer tissue In vitro. Am J Clin Pathol 1953; 23:218-227.
7. Fruehauf J, Bosanquet A. In vitro determination of drug response: a discussion of clinical applications. In: De Vita V, Hellman S, Rosenburg S (editors): Principles and Practice of Oncology Updates 7. Philadelphia, PA: Lippincott; 1993, pp. 1-16.
8. Weisenthal LM, Nygren R Current status of cell culture drug resistance testing (CCDRT). Hum Tumor Assay J 2002; www.weisenthal.org.
9. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 1999; 17:1625-1631.
10. Xu JM, Song ST, Tang ZM, Liu XQ, Jiang ZF, Zhou L, et al. Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer. Breast Cancer Res Treat 1998; 49:251-259.
11. Larsson R, Nygren P. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 1990; 46:67-72.
12. Csoka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1997; 72:1008-1012.
13. Nygren P, Fridborg H, Csoka K, Sundstrom C, de la Torre M, Kristensen J, et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994; 56:715-720.
14. Kristensen J, Jonsson B, Sundstrom C, Nygren P, Larsson R. In vitro analysis of drug resistance in tumor cells from patients with acute myelocytic leukemia. Med Oncol Tumor Pharmacother 1992; 9:65-74.
15. Nygren P, Hagberg H, Glimelius B, Sundstrom C, Kristensen J, Christiansen I, et al. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay. Ann Oncol 1994; 5(suppl 1):127-131.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
17. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994; 54:163-170.
18. Fridborg H, Nygren P, Larsson R. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs 1995; 6:64-69.
19. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50:177-185.
20. Larsson R, Nygren P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res 1993; 13:1825-1829.
21. Larsson R, Nygren P. Cytotoxic activity of topoisomerase Ii inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer 1994; 74:2857-28562.
22. Ericsson SM, Larsson RL, Nygren HP, Sundstrom C, Glimelius BL. Assessment of drug activity and proliferation ex vivo for prediction of outcome in aggressive non-Hodgkin's lymphomas. Acta Oncol 2002; 41:36-43.
23. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med 2003; 253:46-75.
24. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122:376-385.
25. von Heideman A, Sandstrom M, Csoka K, Tholander B, Larsson R, Bergh J, et al. Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients. Ann Oncol 2000; 11: 1301-1307.
26. Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, et al. Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anticancer Drugs 2002; 13:625-630.
27. Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Poch G, et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3:1527-1533.
28. Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ, Zhou L, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 1999; 53:77-85.
29. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77:258-263.
30. Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, et al. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 2001; 22:278-282.
31. Weisenthal LM, Weisenthal CM, Smith ME, Sanchez CG, Berglund RF. Platinum resistance determined by cell culture resistance testing (CCDRT) predicts for patient survival in ovarian cancer. Hum Tumor Assay J 2003; www.weisenthal.org.
32. Baak JP, Path FR, Hermsen MA, Meijer G, Schmidt J, Janssen EA. Genomics and proteomics in cancer. Eur J Cancer 2003; 39:1199-1215.
33. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
34. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22:2284-2293.
35. Cree IA. Predictive Oncology-Second Conference of the International Society for Chemosensitivity Testing in Oncology. Anticancer Drugs 2004; 15:301-302.
36. Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 2003; 8:252-258.